首页|METTL16在多发性骨髓瘤患者中的临床应用价值

METTL16在多发性骨髓瘤患者中的临床应用价值

The clinical application value of METTL16 in patients with multiple myeloma

扫码查看
目的 探究甲基转移酶样蛋白16(METTL16)在多发性骨髓瘤(MM)患者临床诊断及对预后预测的应用价值.方法 在多发性骨髓瘤研究基金会(MMRF)及基因型-组织表达项目(GTEx)数据库中分析参与N6-甲基腺苷(m6A)修饰的各基因在MM中表达水平及预后潜力.分别收集 26例初次诊断MM患者及19 例标准方案治疗后MM患者骨髓标本和 24 例正常人外周血标本,采用 qRT-PCR 技术测定m6A各基因表达量;同时收集MM初诊患者各实验室及临床指标:血红蛋白(Hb)、白细胞数(WBC)、血小板数(PLT)、血肌酐(Scr)、血清钙离子(Ca2+)、β-微球蛋白(β-MG)、骨破坏、ISS分期、分型、生存期(OS),对上述指标进行 MET-TL16 相关性分析.进一步检测标本中:白细胞介素(IL)-4、IL-6、IL-10、IL-18 及趋化因子(CCL)2、CCL3、CCL4 表达水平,并对其与METTL16 表达的相关性进行分析.结果 数据库分析提示METTL16 在MM患者样本中较正常对照表达显著升高,与不良预后相关.qRT-PCR结果显示,MM初诊患者骨髓中METTL16 表达水平显著高于治疗后患者以及正常对照组.其表达与血红蛋白、白细胞、骨破坏及分期、生存期等均有相关性,且其表达与CCL4 表达呈正相关.结论 METTL16 在MM患者中高表达,其表达水平与贫血、更严重的骨质破坏及更晚的分期等相关,可能提示不良预后.METTL16 与CCL4 表达有显著相关性,提示其可能通过相关通路发挥相应致病作用.METTL16 在MM的诊疗中将具有重要临床价值.
Objective To investigate the value of methyltransferase-like protein 16(METTL16)in the clinical di-agnosis and prognostic prediction of multiple myeloma(MM)patients.Methods The expression level and prog-nostic potential of each gene involved in N6-methyladenosine(m6A)modification in MM were respectively ana-lyzed in the databases of the Multiple Myeloma Research Foundation(MMRF)and the Genotype-Tissue Expression Project(GTEx).Bone marrow specimens from 26 patients with initial diagnosis of MM and 19 patients with MM af-ter treatment with standard regimens and peripheral blood specimens from 24 normal subjects were collected respec-tively,and the expression levels of m6A genes were determined by qRT-PCR.The correlation between METTL16 expression and various laboratory and clinical indexes was analyzed:hemoglobin(Hb),white blood cell count(WBC),platelet count(PLT),blood creatinine(Scr),serum calcium(Ca2+),β-microglobulin(β-MG),bone destruction,ISS stage,type,and overall survival(OS)in the patients with primary diagnosis.The expression lev-els of interleukin(IL)-4,IL-6,IL-10,IL-18 and chemokine ligand 2(CCL2),CCL3,CCL4 in the specimens were further examined and their correlation with the expression of METTL16 was investigated.Results Database a-nalysis suggested that METTL16 expression was significantly higher in MM patient samples compared with normal controls,which was associated with poor prognosis and had certain diagnostic value.qRT-PCR results showed that the expression level of METTL16 in the bone marrow of patients with initial diagnosis of MM was significantly higher than that of treated patients and normal controls.Its expression was positively correlated with hemoglobin,leuko-cytes and stage,and its expression was positively correlated with CCL4 expression.Conclusion METTL16 expres-sion was significantly elevated in patients with MM,and its expression level was correlated with anemia,more bone destruction and worse stage,which might indicate a poor prognosis.The significant correlation between the expres-sion of METTL16 and CCL4 suggests that METTL16 may play a corresponding pathogenic role through the relevant pathway.METTL16 will have significant clinical value in the management of MM.

multiple myelomam6AMETTL16inflammatory factorchemokinesCCL4

汪万杰、许晗、许婷婷、鲍静、夏瑞祥

展开 >

安徽医科大学第一附属医院血液内科,合肥 230022

多发性骨髓瘤 N6-甲基腺苷 甲基转移酶样蛋白16 炎症因子 趋化因子 CCL4

安徽省自然科学基金

2008085MH296

2024

安徽医科大学学报
安徽医科大学

安徽医科大学学报

CSTPCD北大核心
影响因子:1.095
ISSN:1000-1492
年,卷(期):2024.59(4)
  • 15